Other studies have reported that DSF treatment alone can effectively enhance in vivo anti-cancer immunity, which are attributed to mechanisms independent of Cu, such as inducing PD-L1 up-regulation by suppressing DNMT1 expression and activity 61 or inhibiting the accumulation and polarization of tumor-suppressive macrophages by targeting FROUNT 23. Here, NUP85 is linked to neoplasm.